论文部分内容阅读
目的观察气血并治方对下肢动脉硬化闭塞症(ASO)股动脉支架植入后的临床疗效。方法选择ASO股动脉支架植入患者120例(142条患肢),随机分为中药组60例(72条患肢),对照组60例(70条患肢)。所有患者均予长期口服抗血小板药物治疗,中药组加用气血并治方口服。观察两组患者术后6、12、24个月间歇性跛行、静息痛、截肢情况、踝/肱指数(ABI)、血管通畅率等。结果两组患者术后6、12、24个月与本组术前比较,间歇性跛行、静息痛均明显改善(P<0.01)。术后6、12个月中药组与对照组比较间歇性跛行、静息痛症状差异无统计学意义(P>0.05),术后24个月间歇性跛行明显降低(P<0.05)。对照组与中药组患者术后6个月血管通畅率分别为83%(45/54例)、88%(46/52例);12个月分别为69%(37/54例)、81%(42/52例);24个月分别为54%(29/54例)、77%(40/52例)。两组术后6个月和12个月血管通畅率差异无统计学意义(P>0.05);中药组术后24个月血管通畅率显著高于对照组(P<0.05)。两组患者术后6、12、24个月ABI与本组术前比较差异有统计学意义(P<0.01)。术后6个月中药组ABI与对照组比较差异无统计学意义(P>0.05),术后12个月、24个月中药组ABI较对照组显著增加(P<0.05)。结论气血并治方可明显提高ASO患者股动脉支架术后血管通畅率,改善肢体缺血症状。
Objective To observe the clinical curative effect of Qixue Jianzhi on lower extremity arteriosclerosis obliterans (ASO) femoral artery stent implantation. Methods A total of 120 patients (142 limbs) with ASO femoral artery stenting were selected and randomly divided into 60 cases (72 limbs) in the TCM group and 60 cases (70 limbs) in the control group. All patients were given long-term oral anti-platelet drug therapy, Chinese medicine group plus qi and blood treatment prescription oral. At 6, 12, and 24 months after operation, intermittent claudication, rest pain, amputation, ankle / brachial index (ABI) and vascular patency rate were observed. Results The two groups of patients at 6,12,24 months after surgery compared with the preoperative group, intermittent claudication, rest pain were significantly improved (P <0.01). The symptoms of intermittent claudication and resting pain were not significantly different between the Chinese medicine group and the control group at 6 and 12 months after operation (P> 0.05). Intermittent claudication was significantly decreased at 24 months after operation (P <0.05). The vascular patency rate in the control group and the traditional Chinese medicine group was 83% (45/54) and 88% (46/52) respectively at 6 months after operation, 69% (37/54) at 12 months, 81% (42/52 cases), 54% (29/54 cases) and 77% (40/52 cases) in 24 months respectively. There was no significant difference in vascular patency rate between the two groups at 6 months and 12 months postoperatively (P> 0.05). The patency rate of the 24 months postoperatively in the TCM group was significantly higher than that of the control group (P <0.05). There was significant difference in ABI between the two groups at 6, 12, and 24 months after operation (P <0.01). There was no significant difference in ABI between the Chinese medicine group and the control group 6 months after operation (P> 0.05). The ABI of Chinese medicine group at 12 months and 24 months after operation was significantly higher than that of the control group (P <0.05). Conclusion Qixue Bingzhi can significantly improve postoperative vascular patency rate and improve limb ischemia in ASO patients.